STAT+: A new AI tool aims to help surgeons quickly analyze brain tumor mutations during surgery
When it comes to treating brain tumors, sometimes less is more in the operating room….
Category: STAT+
STAT+: Brazilian committee says a Vertex cystic fibrosis is not cost-effective and should not be reimbursed
A Brazilian government advisory committee recommended that the health ministry not pay for a cystic…
STAT+: FDA withdraws approval of controversial drug to prevent preterm births
After a years-long controversy, the U.S. Food and Drug Administration ordered the immediate withdrawal of a…
STAT+: To make immunotherapy safe for brain tumors, researchers will have to tackle new risks
The success of CAR-T immunotherapies against blood cancers has raised hope that CAR-T can bring…
STAT+: Pharmalittle: Weight-loss drug ads pose new oversight challenge; will the new Bayer CEO split the company?
Rise and shine, another busy day is on the way. We can tell because the…
STAT+: With Apollo Endosurgery acquisition, Boston Scientific dives into the obesity treatment market
The landscape of obesity treatment is quickly changing — and with its acquisition this week…
STAT+: With weight loss drug ads, telehealth companies wade into a regulatory gray area
They’ve swiftly caught the attention of subway goers: splashy ads plastered on train station walls…
STAT+: Research misconduct allegations put Stanford’s president — and science — under an uncomfortable spotlight
STANFORD, Calif. — It’s the one thing everyone knows. And it’s the last thing people…
STAT+: Medicare Advantage plans will have to stop denying required care, federal officials say
The Biden administration is moving forward with proposals that would crack down on Medicare Advantage…
STAT+: Former Magellan Diagnostics execs charged with selling defective lead testing machines used for kids
Three former executives at Magellan Diagnostics Inc. are charged with knowingly selling defective lead testing…
STAT+: Cancer drug shortages have plagued the U.S. for years. Can they be fixed?
Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members…
STAT+: Pharmalittle: J&J agrees to settle talcum powder claims for $8.9 billion; FDA authorizes new severe-Covid therapy
Good morning! Jason Mast here, filling in for Ed on this fine Passover eve. Every…
STAT+: ‘True disruption’: Mark Cuban’s company will sell brand-name diabetes medicines from Janssen
For the first time, Mark Cuban’s Cost Plus Drug Company is selling medicines made by…
STAT+: Pharmalittle: A ‘King Kong’ of weight-loss drugs is looming; FTC orders Illumina to divest Grail
Hello, everyone, and how are you today? We are doing just fine, thank you, since…
STAT+: From a public library whiteboard, a $350 million biotech venture fund
A new biotech VC firm started by veterans of the industry began around a whiteboard…
STAT+: The Q2 health tech tracker: 13 key industry events and milestones to watch
Health tech companies are still plagued by a sluggish funding environment and a wobbling economy…
STAT+: FTC tells Illumina to divest Grail, boosting Icahn’s case
The U.S. Federal Trade Commission on Monday ordered DNA sequencing giant Illumina to divest Grail,…
STAT+: Pharmalittle: FDA slams company recalling eye drops over manufacturing issues; U.S. funds massive Alzheimer’s research database
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
.jpg)
STAT+: Vertex, CRISPR Therapeutics inch ahead of rival for genetic fix to sickle cell disease
The first CRISPR treatment for sickle cell disease has been submitted to the Food and…
.jpg)
STAT+: A devastating skin condition could soon get its first medication, as the frontiers of gene therapy expand
Wounds have been a constant fact of Aaron Owens’ life. His skin is so fragile…
STAT+: The biotech scorecard for the second quarter: 24 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second…
STAT+: Biden administration goes easy on Medicare Advantage insurers after intense industry lobbying
WASHINGTON — The Biden administration backed off some of its plans to rein in billions…
STAT+: European Union drug pricing proposal for the pandemic treaty generates pushback
Amid treaty talks to create equitable access to medical products during pandemics, the European Union…
STAT+: Inflation caused a sizable drop in net drug prices in late 2022, analysis finds
Amid ongoing debate over the cost of prescription medicines, a new analysis finds that brand-name…
STAT+: FDA report details problems at Global Pharma plant involved in eye drop recall
Global Pharma Healthcare, whose eye drops have been linked to dozens of serious reactions, failed…
STAT+: Pharmalittle: Judge blocks required ACA coverage for preventive care; Supreme Court urged to review skinny label case
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: 3 keys to successful biopharma-academia drug development collaborations
Academia can be an excellent source of novel drug targets and new technologies that can…
STAT+: Solicitor General urges Supreme Court to review ‘skinny labeling’ and generic drug access
The U.S. solicitor general urged the U.S. Supreme Court to review a controversy over so-called…
STAT+: Drug middlemen switch tactics, but the outcome is the same: high prices
WASHINGTON — Prescription drug middlemen are shifting away from rebates that have been blamed in…
STAT+: FDA proposes a new plan to streamline updates to medical devices that use AI
The Food and Drug Administration on Thursday released a new plan allowing developers of medical…
STAT+: Pharmalittle: FDA approves over-the-counter Narcan; J&J exits the race for the first RSV vaccine
Rise and shine, another busy day is on the way. We can tell because the…
STAT+: Former J&J exec, an in-demand free agent, takes the helm at privately held FogPharma
Mathai Mammen, who until recently led research at Johnson & Johnson, will become the CEO…
STAT+: Is there $21 billion left for Covid response, or $5 billion? The White House is using fuzzy math
WASHINGTON — How much money does the federal government still have set aside for the…
STAT+: Dutch health minister won’t cover a Gilead cancer drug due to the cost
In a rare move, the Dutch health ministry refused to provide coverage for a Gilead…
STAT+: NIH releases data showing more clinical trial sponsors are reporting results, but most miss deadlines
In response to mounting criticism, the National Institutes of Health published data that shows an…
STAT+: New research may give geneticists a long-sought tool: a targeted protein delivery device
Mark Hurst just wanted to kill some bugs. A newly credentialed bacteriologist working for the…
STAT+: British Columbia to bar Americans from buying Ozempic over supply concerns
British Columbia plans to limit sales of the popular diabetes drug Ozempic to Canadian residents…
STAT+: Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Medical device companies now need to prove to FDA they’re protected against cyber attacks
Hidden in this year’s federal spending bill, among major changes to Medicare payments to doctors…
STAT+: Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs
A growing shortage of monkeys used for early-stage pharmaceutical research is causing concern that many…
STAT+: Oscar Health names former Aetna executive as new CEO
The tech-forward insurer Oscar Health has tapped former Aetna CEO Mark Bertolini to be its…
STAT+: Pharmalittle: Ohio attorney general accuses PBMs of price fixing; how cost-effectiveness fight could hobble drug price negotiations
Top of the morning to you. Steely gray skies are hovering over the Pharmalot campus…
STAT+: With new study data, Intra-Cellular could expand use of approved mood-disorder treatment
Intra-Cellular Therapies, maker of an approved treatment for schizophrenia and bipolar depression, announced positive results…
STAT+: Viking Therapeutics releases early but promising weight loss data on new GLP-1 drug
Viking Therapeutics, a small biotechnology company, said Tuesday that its experimental medicine led patients to…
STAT+: As AI promises to revolutionize medical note-taking, concerns mount about accuracy and harm
In the doctor’s offices of the future, artificial intelligence will be a fly on the…
STAT+: Could a fight over cost-effectiveness upend Medicare drug price negotiation before it’s begun?
WASHINGTON — As Medicare drug price negotiation looms, congressional Republicans are scrambling to push through…
STAT+: Novartis data set up multibillion-dollar battle over breast cancer drugs
Novartis announced data Monday that could set up one of the biggest marketing battles in…
STAT+: Ohio attorney general accuses pharmacy benefit managers of drug price fixing
The Ohio attorney general filed a lawsuit on Monday accusing three large pharmacy benefit managers…
STAT+: Bernie Sanders’ accidentally great drug pricing idea
When Moderna CEO Stéphane Bancel was called before a Senate committee last week to defend…
STAT+: Pharmalittle: FDA proposes more rigorous cancer drug trials for accelerated approval; insurers not covering obesity meds for kids
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…